OBM Integrative and Complementary Medicine is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. It covers all evidence-based scientific studies on integrative, alternative and complementary approaches to improving health and wellness.

Topics contain but are not limited to:

  • Acupuncture
  • Acupressure
  • Acupotomy
  • Bioelectromagnetics applications
  • Pharmacological and biological treatments including their efficacy and safety
  • Diet, nutrition and lifestyle changes
  • Herbal medicine
  • Homeopathy
  • Manual healing methods (e.g., massage, physical therapy)
  • Kinesiology
  • Mind/body interventions
  • Preventive medicine
  • Research in integrative medicine
  • Education in integrative medicine
  • Related policies

It publishes a variety of article types: original research, review, communication, opinion, case report, study protocol, comment, conference report, technical note, book review, etc.

There is no restriction on paper length, provided that the text is concise and comprehensive. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility. 

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 6 days from acceptance to publication (median values for papers published in this journal in the first half of 2019, 1-2 days of FREE language polishing time is also included in this period).

Free Publication in 2019
Current Issue: 2019  Archive: 2018 2017 2016
Open Access Review
Healthcare Provider’s Guide to Kratom: Succinct Introduction to the Basics and the Questions

Joseph V. Pergolizzi 1, 2 , Robert Taylor 1 , Robert B. Raffa 2, 3, 4, * , Jo Anne LeQuang 1

  1. NEMA Research, Naples, FL, USA
  2. Neumentum, Palo Alto, CA, USA
  3. Temple University (Emeritus), Philadelphia, PA, USA
  4. University of Arizona (Adjunct), Tucson, AZ, USA

*   Correspondence: Robert B. Raffa

Academic Editor: James D. Adams

Special Issue: Complementary and Alternative Medicine in Nervous System Conditions

Received: July 27, 2018 | Accepted: December 25, 2018 | Published: December 28, 2018

OBM Integrative and Complementary Medicine 2018, Volume 3, Issue 4 doi: 10.21926/obm.icm.1804038

Recommended citation: Pergolizzi JV, Taylor R, Raffa RB, LeQuang JA. Healthcare Provider’s Guide to Kratom: Succinct Introduction to the Basics and the Questions. OBM Integrative and Complementary Medicine 2018;3(4):038; doi:10.21926/obm.icm.1804038.

© 2018 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.

Abstract

Background: The leaves of Mitragyna speciosa (kratom), a tropical tree that is indigenous to Southeast Asia, have been used traditionally to increase stamina, as a digestive aid, and as an analgesic. Kratom use is now increasingly popular in the rest of the world because of easy availability through the Internet and real, or perceived, views of efficacy and safety.

Methods: PubMed and MedLine searches were conducted of published articles available in English.

Results: Mitragynine and 7-hydroxymitragynine are the primary psychoactive compounds of the over 25 alkaloids in kratom. Subjective effects are dose dependent: a mild stimulation at lower doses, sedative effects at intermediate doses, and mild opioid-like effects at higher doses. Toxicity is rare and may be due instead to polypharmacy. Abrupt discontinuation after extensive use can produce withdrawal symptoms, but use does not imply overt dysfunction or decreased quality of life. In fact, Kratom has been used by opioid substance abusers as a means of easing withdrawal. Indeed, the use of kratom as a safer choice than opioids is an argument against overzealous regulatory control. Potential therapeutic utility as a mixed-acting analgesic agent, anti-inflammatory, and possibly anticancer agent are currently being investigated.

Conclusions: Kratom or one or more of its constituent substances likely have important therapeutic potential – or as drug-discovery leads – as analgesics, treatment or prevention of opioid use disorder, and possibly other medical conditions. Since its use as a recreational drug is also on the rise, it is imperative that healthcare providers and regulators maintain an open mind and support the need for more basic and clinical research to help elucidate the actual potential medical benefits and potential adverse effects of this simultaneously old, yet new, pharmacologic agent.

Keywords

Kratom; pharmacology; therapy; opioid-abuse treatment

1. Introduction

Mitragyna speciosa (kratom) is a tropical tree of the Rubiaceae family (of which coffee is also a member) that is indigenous to Southeast Asia. Leaves from the tree (see Figure 1) are traditionally used (chewed) by laborers to increase energy and stamina [1], or for medicinal purposes such as pain relief, digestive disorders, and even to attenuate morphine withdrawal [2].

Figure 1 Kratom plant (photo credit: Wikimedia Commons).

Kratom has become increasingly popular and visible in the rest of the world in recent years [3]. As a natural substance with a long history, this ethnodrug known variously as ‘kratom’, ‘ketum’, ‘biak’ (Malaysia), or ‘krathom’ (Thailand) among others, is both scientifically interesting and a potential concern to healthcare providers and regulatory agencies because not enough is understood about its pharmacologic or adverse effects. Complicating things, as an unregulated natural product, the exact composition of a given commercial product is often unknown.

2. Materials and Methods

Online sources such as PubMed, MedLine, and news media were searched for publications and articles available in English with titles or search terms relevant to the topic. Search terms included kratom (and regional synonyms such as biak, etc.), mitragyna, mitragynine, 7-hydroxymitragynine, plus terms related to specific pharmacology (e.g., mu- delta- and kappa-opioid receptors, affinity, efficacy, biased ligand, etc.). References within each citation were also searched. To the best of our ability the pertinent information, or at least the essence of the information, has been distilled herein from the several hundred ‘hits’.

3. Results

3.1 From Traditional to Contemporary Use

Kratom has been used for centuries by manual laborers in Southeast Asia countries to enhance mental-alertness and increase stamina. In some communities, kratom leaves have also been part of traditional folk medicine, and as such it has been used to treat a variety of medical conditions, including diabetes, fever, and diarrhea. Its efficacy for pain-relief (analgesic agent) is well known to traditional practitioners [4]. It is sometimes also used as part of religious ceremonies and at social and community gatherings [5]. Until recently, Malaysia and Thailand were the main geographical areas of kratom use. Surveys reported lifetime prevalence of use of about 2% [6] to 5% [7].

However, although kratom is legal in parts of the world, including much of the United States, it is not devoid of potential problems. For example, kratom is the most frequently used illegal drug in Thailand [8]. It is also illegal in Malaysia, but it may be more openly available from suppliers and coffee shops [9]. Thailand very recently approved the use of kratom plants for medicinal use. In the West, kratom can be obtained from online sources and from specialty shops and bars [10]. Some Internet sources of kratom market it as a supplement or herbal product, which may lead certain purchasers into thinking that the product is completely harmless because it is a “natural” substance [10,11]. The legal status of the drug in the United States allows people to use the drug without exposure to legal risks. It has even been promoted as a “safe, legal high.” [3,11].

Multiple sources provide kratom powder made from dried leaves [12]. Consumption patterns can vary by location (with much overlap): chewing kratom is common in Thailand, drinking kratom-infused beverages is more common in Malaysia, and powders and capsules are more popular in the West [13]. Historically, kratom leaves (fresh or dried) have been brewed into a tea, smoked or chewed [14], which is how manual laborers in rural Southeast Asia came to be known as “kratom eaters” for the habit of chewing fresh leaves throughout the day [1]. The leaves have a bitter and unpleasant taste, so some users prefer to make it more palatable by infusing it into tea, coffee, or other beverages and adding milk, sugar, or other flavorings. Recently, “4 x 100” cocktails are being used by young people in countries that prohibit alcohol (the name from the four main ingredients of a sweet caffeine-containing beverage, kratom, codeine, and variably some antidepressant or anxiolytic drug, served over ice, yielding a drink that reportedly mimics the effects of liquor) [6,15].

Although Malaysia strictly regulates kratom and penalizes possession [3], rural communities do not look down on its use by laborers, provided that the use is for work to support their families [1]. There is little discrimination or disrespect for kratom users, although some family members may rebuke regular users for spending too much money on their ‘habit’ [2]. In fact, Southeast Asia kratom users may be viewed by their peers as particularly diligent people, taking advantage of the drug’s energizing effects in order to work longer hours and earn more money for their families [1]. And in contrast to individuals who use other substances, habitual kratom users in Southeast Asia tend to be older, married, and living together with the families that they support [1,7,9].

In the West, kratom has historically been viewed as something of a novelty, a natural herbal product with possible therapeutic benefits, or even as a legal high. Many in the West still view kratom as mild and completely harmless, partly because it is considered a natural substance and partly because there are few laws restricting its use.

It is not known if long-term excessive use of kratom leads to social, physical, or psychological problems [3]. Kratom use can lead to the development of physical dependence and withdrawal symptoms upon too abrupt discontinuation [16]. However, the assumption by some that these are definitive signs of ‘addiction’ is outdated and inaccurate, since they are physical phenomena that result from basic pharmacologic principles and apply to almost all drugs.

3.2 Kratom and the Law

The laws regarding kratom can be convoluted, complex, or altogether confusing. For example, kratom has been technically outlawed in Thailand since 1943 [3], where it is illegal to plant, grow, possess, import, or export kratom leaves [7]. Nevertheless, kratom is widely used in Thailand and users do not experience particular social stigma. Now, Thailand has very recently approved the use of kratom plants for medicinal use. Kratom is a controlled substance in Australia, Bhutan, Malaysia, Myanmar, and other countries [17], but it is legal to cultivate kratom in Malaysia as long as it is not consumed, distributed, or prepared for distribution (leaving one to wonder what else is there) [9].

Only a few European nations have regulations specifically addressing kratom [18], and kratom is largely uncontrolled in the United States (but there is currently a very intense debate on this subject) [13]. This may also make it particularly appealing to risk-averse recreational users [19]. While the United States and United Kingdom do not regulate kratom, the United States Food and Drug Administration (FDA) has issued an import-alert warning about possible side effects [20]. And the United States Drug Enforcement Administration (DEA) has added kratom to its list of “Drugs and Chemicals of Concern.” [21,22]. The FDA has seized certain products containing kratom, but typically only in products where kratom is used in dietary supplements. The import-alert of 2014 allows officials to interdict such products when the agency believes that the product is adulterated [20]; the United States Department of Justice has ruled that kratom is a dietary ingredient for which there is not sufficient reasonable assurance that it does not present risk of illness or injury. Large seizures of imported dietary supplements containing kratom have occurred [23,24].

3.3 Pharmacologically Active Compounds in Kratom

The main active compounds in kratom leaves are the alkaloids mitragynine and 7-hydroxymitragynine, plus speciogynine, paynantheine, and speciociliatine [6]. It contains dozens of different but structurally related alkaloids along with flavonoids, terpenoid saponins, polyphenols, and glycosides [3].

The alkaloid content of kratom is about 0.5% to 1.5% [25,26], which varies from plant to plant, and depends upon the strain, its location of cultivation and the season [27]. Mitragynine is lipophilic, with poor solubility in water [28]. The alkaloid fraction of mitragynine can be as high as 66% for kratom from Thailand or as low as 12% for kratom from Malaysia [29]. Although structurally dissimilar to morphine and other opioids, mitragynine has some affinity for opioid receptors [30]. All of the mitragynine analogs in kratom (e.g., speciogynine, paynantheine, and speciociliatine) are indole alkaloids with a monoterpene moiety [29]. 7-Hydroxymitragynine is more potent than mitragynine in in vitro and in vivo tests [29,31,32].

Botanically, there are three main strains of kratom. The red variety originated in Bali and is known in folk medicine as an effective pain reliever. The green and white varieties originated in Malaysia and have a reputation for their stimulating effects [33]. Buyers who shop online may find “brand names” such as Bali kratom, Malaysian kratom, Thai kratom, Maeng Da kratom, white-veined Borneo kratom, Java kratom, Sumatra red, and so on [27]. Online sellers have attempted to rank kratom by grade in terms of potency with “organic commercial grade” the least and “super” or “super enhanced” the most potent forms [33]. However, these grades are marketing terms used by those selling kratom and have not been subjected to any form of scientific scrutiny or objective analysis.

3.4 Pharmacology

The exact pharmacological mechanism(s) responsible for producing kratom’s characteristic effects have yet to be established [34,35,36,37], Some of the earliest work on the basic science of kratom was done by Macko et al. [38], who reported among other things the antinociceptive effects of mitragynine in mice (hot-plate test), rats (tail-flick and paw-pressure tests), and dogs (hindleg flick). The pharmacologic response to kratom [3] varies among individuals, which might result from kratom’s hydrophobicity, poor solubility in water, variable drug release in body fluids, and variable acid degradation properties. Kratom’s subjective effects depend on dose: stimulation is characteristic of low doses, analgesia and sedative effects of higher doses [39]. Interesting recent studies suggest that the differences from traditional poppy-derived opioids might be attributable to the G protein ‘biased signaling’ nature of interaction at the mu-opioid receptor [40,41].

Kratom is mainly metabolized in the liver [42,43]. In a study on human recombinant cytochrome P450 (CYP450) enzymes, mitragynine produced a strong inhibitory effect on CYP3A4 and CYP2D6, moderate inhibition of CYP1A2, and weak inhibition of CYP2C19. This suggests that concomitant use of kratom and other drugs that act as substrates of these enzymes might result in potential drug interactions [6,25,44]. In a pharmacokinetic study of healthy subjects who regularly used kratom, mitragynine levels declined exponentially, suggesting a two-compartment model [45]. About 0.14% of mitragynine was excreted unchanged in the urine [45].

3.5 Adverse Effects and Toxicity

Oral doses of total alkaloid extract of Matrigyna speciosa at 200 mg/kg were lethal to rats [46]. The lethal dose 50% (LD50) for mice was 477 mg/kg for mitragynine and 591 mg/kg for alkaloid extract [39]. The therapeutic index for the alkaloid extract compared to mitragynine was 3:1 and 20:1, respectively [28].

The literature contains a few reports of putative kratom-related fatalities, but most involve poly-substance use, so it is difficult to attribute causality [47]. Preclinical reports or individual case reports of excess kratom use have suggested adverse effects, but more well-validated clinical research is clearly needed [17,48,49,50,51,52,53].

Those who used kratom regularly over extended periods of time have reported weight loss, dehydration, constipation, hyperpigmentation, lethargy, and fatigue [9]. Other adverse effects, including trembling hands and headaches, have also been reported [7].

3.6 Abuse Potential

Kratom appears to have some potential for abuse [1,7,8]. And abrupt discontinuation of regular kratom use can produce mild withdrawal symptoms (e.g., irritability, lethargy, yawning, rhinitis, muscular aches and pains, cramps, and diarrhea) [1,8]. ‘Psychological’ withdrawal symptoms are reported also (tension, restlessness, aggression, sadness, delusions, hallucinations, moodiness, anxiety, and cravings) [8,16]. Other reports add insomnia and pruritus [54]. The withdrawal symptoms may persist for a few days [16], but compared to withdrawal from other substances, the kratom experience has been described as generally shorter and not as distressing [16]. Regular kratom users in Malaysia did not exhibit social dysfunction compared to non-users, and none were involved in criminal activities to support their habit [55].

Concern of potential abuse is expressed because low doses act as a stimulant and therefore might pose the risk of a milder version of the stimulation produced by amphetamines or cocaine, and higher doses produce more sedative effects, possibly posing the risk of a milder version of opioids [56,57,58]. In some preclinical studies, mitragynine has been reported to be mildly rewarding, or to impair learning and memory [51,59,60]. But recent studies have shown that mitragynine is not self-administered by rats [61,62].

Dose-dependent stimulatory and sedative effects of kratom, potentially attractive to some users, suggests that a small subset will abuse it, as occurs in locations where the plant grows indigenously [1]. Ready Internet access, and low price also suggest that it will become increasingly popular among recreational users [9]. On the other hand, the use of kratom instead of dangerous drugs of abuse would represent a net plus to individuals and society. Hence the on-going regulatory debate.

Kratom constituents are not currently detectable in conventional urine drug screening assays, but chromatography-tandem or ion-mass spectrometry instruments can detect kratom [3,10,13]. Kratom was added to the Monitoring List of the World Anti-Doping Agency in sports in 2014. There are currently no standardized screens for mitragynine other than liquid chromatography-mass spectrometry [25].

3.7 Clinical Response to Kratom Toxicity

Kratom toxicity has been reported, but mainly in the form of case reports – and almost always involving polysubstance use – making it difficult to draw conclusions. The symptoms of kratom toxicity have been reported to include heart palpitations, seizures, and coma [63,64]. One case of intrahepatic cholestasis has been described in a young male who used kratom for two weeks [49]. The literature reports fatalities associated with the use of kratom, but polydrug use is almost always involved [41,44,63,65]. The relative toxicity of mitragynine and 7-hydroxymitragynine remains to be elucidated. Reports almost never include the relative concentrations, which may or may not be an important consideration [66].

Patients with kratom overdose should be considered for detoxification, which should be undertaken in clinic. The clinical team should ascertain what the patient took and if multiple substances might be involved – which is highly likely. Patients undergoing withdrawal should receive supportive care and should be treated in accordance with detoxification protocols.

3.8 Clinical Response to Kratom Dependence/Abuse

The literature reports a case of “addiction” and detoxification in a 37-yr Caucasian woman who was introduced to kratom by a colleague for pain control. She soon began buying kratom online because in addition to analgesic benefits, it gave her the added energy that helped her manage her busy schedule [67]. She presented in kratom withdrawal and was initiated on an opioid withdrawal protocol in the hospital using symptom-triggered clonidine at a dose of from 0.1 to 0.2 mg/kg every two hours based on her Clinical Opioid Withdrawal Scale (COWS) score; she also was administered 50 mg oral hydroxyzine every six hours and 0.1 mg/day clonidine via a transdermal patch. She experienced severe withdrawal symptoms on the COWS scale which improved rapidly by the third day. Following detoxification, she experienced symptoms of depression and was discharged from hospital with counseling and oral naltrexone 50 mg [67]. There is no current consensus as to the best way to manage kratom withdrawal. It has been suggested that combination therapy including alpha-2 agonists and hydroxyzine may be efficacious in relieving the physical and mental symptoms [67]. Once the patient has successfully discontinued kratom, maintenance strategies are also unclear. While it has been suggested that buprenorphine or methadone be used as maintenance therapy, kratom is not of the opioid class and this raises regulatory issues regarding the appropriateness of using opioids for kratom maintenance [67]. Naltrexone (an opioid antagonist) may be helpful in that it may attenuate cravings, as it does for alcohol [67].

4. Discussion

As kratom use increases in the United States, people will seek advice from clinicians about it, because they have used it, want to try it, or because they are concerned about another person using it. Some patients may believe or assume that it is a safe herbal supplement or some kind of natural pain reliever. Others think it should be outlawed entirely. Clinicians should know the legal status of kratom in their state and municipality and remind patients that although it is a natural (and often legal) substance, it can still have as yet unknown potential adverse effects.

4.1 Kratom’s Potential Role for the Treatment of Opioid Withdrawal

Kratom is sometimes used as a safer, legal alternative to other substances [9,13]. It has also been used to help relieve opioid withdrawal symptoms and as an aid for those seeking to discontinue opioid use [9]. Migration from opioid use to kratom use has been documented in Southeast Asia [5]. Clinical trials of the value of kratom for treatment of opioid abuse and of alleviating withdrawal symptoms is a topic worthy of further study.

4.2 Therapeutic Potential of Kratom

The components of kratom have been studied in a variety of preclinical in vitro and in vivo tests [10,25,56,68,69]. Methanolic and alkaloid extracts significantly prolonged response latency in the hot-plate test, indicative of analgesic activity [70,71]. Mitragynine had antinociceptive properties when administered either orally or intraperitoneally to rats [72]. Oral or subcutaneous mitragynine produced potent antinociceptive effect in the tail-flick and hot-plate tests in mice [73].

Kratom is sometimes marketed—openly—as an herbal supplement for pain control [53,74,75]. The analgesic properties of kratom and those of its major active principal mitragynine are subjects worthy of study in clinical trials.

Mitragynine may also exert an anti-inflammatory effect [29,30] by suppressing prostaglandin E2 (PGE-2) in the cyclooxygenase (COX) 2 pathway [32]. It has also been suggested that mitragynine may possess anticancer properties [76]. Kratom extracts and mitragynine have displayed cytotoxicity to certain human cancer cell lines (e.g., SH-SY5Y) [77]. Mitragynine may modulate muscle neurogenic contraction [78,79,80], and gastric secretion [81], consistent with traditional use. There are also anecdotal reports that it has aphrodisiac properties [9].

5. Conclusions

Kratom, long used in Southeast Asia as a work-enhancing energizer and traditional remedy, is rapidly growing in use in the West as a result of availability through the Internet, aided in part by its current non-scheduled status and perception by some that it offers a safe all-natural high. In low doses users experience a pleasant stimulation, sedation and analgesia at moderate doses, and mild opioid-like effects at high doses. There are reports of withdrawal symptoms if the drug is abruptly discontinued after long-term use. Kratom components – or analogs of them – might have therapeutic potential for several conditions, including pain relief and opioid use disorder. Its use as a recreational drug is very likely to increase, raising a dilemma for healthcare providers and regulators: should it be tightly regulated, or should it be viewed as a better option than ‘hard’ drugs – and therefore controlled more like ethanol. It is important that clinicians familiarize themselves with this substance and how to counsel patients with respect to its use. It is also important that they be proactive in the debate and the decision process regarding scheduling kratom as a controlled substance. It is either the next drug of abuse or a panacea to the opioid crisis – or, most likely, something in between that requires mature, informed decision-making.

Acknowledgments

The authors wish to thank the reviewers for an exceptionally diligent and authoritative review. The manuscript was significantly improved in many ways due to their astute and gracious guidance and recommendations.

Author Contributions

These authors contributed equally to this work

Competing Interests

The authors have declared that no competing interests exist.

References

  1. Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975; 27: 21-27.
  2. Ahmad K, Aziz Z. Mitragnyna speciosa use in the northern states of Malaysia: a cross-sectional study. J Ethnopharmacol. 2012; 141: 446-450. [CrossRef]
  3. Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, et al. Following “the Roots” of kratom (Mitragyna speciosa): The evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries. Biomed Res Int. 2015; 2015: 968786. [CrossRef]
  4. Grewal K. Observations on the pharmacology of mitragynine. J Pharmacol Exp Ter. 1932; 46: 251-271.
  5. Jansen K, Prast C. Ethnopharmacology of kratom and the Mitagyna alkaloids. J Ethnopharmacol. 1988; 23: 115-119. [CrossRef]
  6. European Monitoring Centre for Drugs and Drug Addiction. Kratom (Mitragyna speciosa) drug profile: European Monitoring Centre for Drugs and Drug Addiction; 2015. Available from: http://www.emcdda.europa.eu/publications/drug-profiles/kratom.
  7. Assanangkornchai S, Muekthong A, Sam-Angsri N, Pattanasattayawong U. The use of mitragynine speciosa (“Krathom”), an addictive plant, in Thailand. Subst Use Misuse. 2007; 42: 2145-2157. [CrossRef]
  8. Saingam D, Assanangkornchai S, Geater A, Lerkiatbundit S. Factor analytical investigation of krathom (Mitragyna speciosa Korth) withdrawal syndrom in Thailand. J Psychoactive Drugs. 2016; 25: 1-10.
  9. Vicknasingam B, Narayanan S, Beng G, Mansor S. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010; 21: 283-288. [CrossRef]
  10. Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow...and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol. 2012; 8: 15-32. [CrossRef]
  11. Schmidt MM, Sharma A, Schifano F, Feinmann C. “Legal highs” on the net-Evaluation of UK-based Websites, products and product information. Forensic Sci Int. 2011; 206: 92-97. [CrossRef]
  12. Bikhuk Trading Company. Buy Kratom: Bikhuk; 2016. Available from: http://www.bikhuk.com/p/bikhuk-resellers.html.
  13. Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. Brain Res Bull. 2016. [CrossRef]
  14. Drug Enforcement Administration. Kratom Washington, DC: Drug Enforcement Administration; 2013. Available from: http://www.deadiversion.usdoj.gov/drug_chem_info/kratom.pdf.
  15. Tungtananuwat W, Lawanprasert S. Fatal 4x100; homemade kratom juice cocktail. J Health Research. 2010; 24: 43-47.
  16. Singh D, Muller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014; 139: 132-137. [CrossRef]
  17. United Nations Office on Drugs and Crime. New psychoactive substances: United Nations Office on Drugs and Crime; 2013. Available from: http://www.unodc.org/wdr2013/en/nps.html.
  18. Forrester MB. Kratom exposures reported to Texas poison centers. J Addict Dis. 2013; 32: 396-400. [CrossRef]
  19. Swogger MT, Hart E, Erowid F, Erowid E, Trabold N, Yee K, et al. Experiences of Kratom Users: A Qualitative Analysis. J Psychoactive Drugs. 2015; 47: 360-367. [CrossRef]
  20. Food and Drug Administration. Import Alert 54-15 Rockville, MD: Food and Drug Administration; 2016. Available from: http://www.accessdata.fda.gov/cms_ia/importalert_1137.html.
  21. Drug Enforcement Administration. Kratom Washington, DC: Drug Enforcement Administration; 2016. Available from: https://www.dea.gov/pr/multimedia-library/publications/drug_of_abuse.pdf#page=84.
  22. Drug Enforcement Administration DoJ. Controlled Substances, alphabetical order Washington, DC: Drug Enforcement Administration; 2016. Available from: http://www.deadiversion.usdoj.gov/schedules/orangebook/
    c_cs_alpha.pdf.
  23. FDA. US Marshals seize dietary supplements containing kratom Rockville, MD: Food and Drug Administration 2016. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm480344.htm.
  24. FDA. Kratom seized in California by US Marshals Service Rockville, MD: Food and Drug Administration; 2016. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm515085.htm.
  25. Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. Int J Legal Med. 2016; 130: 127-138. [CrossRef]
  26. Leon F, Habib E, Adkins JE, Furr EB, McCurdy CR, Cutler SJ. Phytochemical characterization of the leaves of Mitragyna speciosa grown in U.S.A. Nat Prod Commun. 2009; 4: 907-910.
  27. Raffa R. Kratom and Other Mitagynines: The Chemistry and Pharmacology of Opioids from a Non-Opium Source. Raffa R, editor. Boca Raton, FL: CRC Press, Taylor and Francis; 2014.
  28. Suhaimi FW, Yusoff NH, Hassan R, Mansor SM, Navaratnam V, Muller CP, et al. Neurobiology of Kratom and its main alkaloid mitragynine. Brain Res Bull. 2016. [CrossRef]
  29. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull. 2004; 52: 916-928. [CrossRef]
  30. Thongpradichote S, Matsumoto K, Tohda M, Takayama H, Aimi N, Sakai S, et al. Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice. Life Sci. 1998; 62: 1371-1378. [CrossRef]
  31. Horie S, Koyama F, Takayama H, Ishikawa H, Aimi N, Ponglux D, et al. Indole alkaloids of a Thai medicinal herb, Mitragyna speciosa, that has opioid agonistic effect in guinea-pig ileum. Planta medica. 2005; 71: 231-236. [CrossRef]
  32. Utar Z, Majid MI, Adenan MI, Jamil MF, Lan TM. Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E(2) production induced by lipopolysaccharide in RAW264.7 macrophage cells. J Ethnopharmacol. 2011; 136: 75-82. [CrossRef]
  33. Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity Induced by “the 3Ks”: Kava, Kratom and Khat. International journal of molecular sciences. 2016; 17. [CrossRef]
  34. Ujvary I. Psychoactive natural products: overview of recent developments. Annali dell'Istituto superiore di sanita. 2014; 50: 12-27.
  35. Matsumoto K, Mizowaki M, Suchitra T, Murakami Y, Takayama H, Sakai S, et al. Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. European journal of pharmacology. 1996; 317: 75-81. [CrossRef]
  36. Yamamoto LT, Horie S, Takayama H, Aimi N, Sakai S, Yano S, et al. Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa. General pharmacology. 1999; 33: 73-81. [CrossRef]
  37. Taufik Hidayat M, Apryani E, Nabishah B, Moklas M, Sharida F, Farhan M. Determination of mitragynine bound opioid receptors. Adv Med Dent Sci. 2010; 3: 65-70.
  38. Ramanathan S, Parthasarathy S, Murugaiyah V, Magosso E, Tan SC, Mansor SM. Understanding the physicochemical properties of mitragynine, a principal alkaloid of Mitragyna speciosa, for preclinical evaluation. Molecules (Basel, Switzerland). 2015; 20: 4915-4927. [CrossRef]
  39. Sabetghadam A, Ramanathan S, Sasidharan S, Mansor SM. Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats. J Ethnopharmacol. 2013; 146: 815-823. [CrossRef]
  40. Backstrom BG, Classon G, Lowenhielm P, Thelander G. [Krypton--new, deadly Internet drug. Since October 2009 have nine young persons died in Sweden]. Lakartidningen. 2010; 107: 3196-3197.
  41. Holler JM, Vorce SP, McDonough-Bender PC, Magluilo J, Jr., Solomon CJ, Levine B. A drug toxicity death involving propylhexedrine and mitragynine. Journal of analytical toxicology. 2011; 35: 54-59. [CrossRef]
  42. Azizi J, Ismail S, Mansor SM. Mitragyna speciosa Korth leaves extracts induced the CYP450 catalyzed aminopyrine-N-demethylase (APND) and UDP-glucuronosyl transferase (UGT) activities in male Sprague-Dawley rat livers. Drug metabolism and drug interactions. 2013; 28: 95-105. [CrossRef]
  43. Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharmacognosy research. 2013; 5: 241-246. [CrossRef]
  44. Kronstrand R, Roman M, Thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. Journal of analytical toxicology. 2011; 35: 242-247. [CrossRef]
  45. Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug design, development and therapy. 2015; 9: 2421-2429.
  46. Azizi J, Ismail S, Mordi M, Ramanathan S, Said M, Mansor S. In vitro and in vivo efects of three different Mitragyna speciosa Korth leaf extacts on phase II drug metabolizing enzymes-glutathione transferases (GSTS). Molecules (Basel, Switzerland). 2010; 15: 432-441. [CrossRef]
  47. Kroonstad R, Roman M, thelander G, Eriksson A. Unintentional fatal intoxications with mitragynine and O-desmethyltramadol from the herbal blend Krypton. Journal of analytical toxicology. 2011; 35: 242-247. [CrossRef]
  48. Harizal S, Mansor S, Hasnan J, Tharakan J, Abdullah J. Acute toxicity study of the standardized methanolic extract of Mitragyna speciosa Korth in Rodent. J Ethnopharmacol. 2010; 131: 404-409. [CrossRef]
  49. Kapp FG, Maurer HH, Auwarter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol. 2011; 7: 227-231. [CrossRef]
  50. Lu J, Wei H, Wu J, Jamil MF, Tan ML, Adenan MI, et al. Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes. PloS one. 2014; 9: e115648. [CrossRef]
  51. Yusoff NH, Suhaimi FW, Vadivelu RK, Hassan Z, Rumler A, Rotter A, et al. Abuse potential and adverse cognitive effects of mitragynine (kratom). Addiction biology. 2016; 21: 98-110. [CrossRef]
  52. Apryani E, Hidayat MT, Moklas MA, Fakurazi S, Idayu NF. Effects of mitragynine from Mitragyna speciosa Korth leaves on working memory. J Ethnopharmacol. 2010; 129: 357-360. [CrossRef]
  53. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction (Abingdon, England). 2008; 103: 1048-1050. [CrossRef]
  54. McWhirter L, Morris S. A case report of inpatient detoxification after kratom (Mitragyna speciosa) dependence. European addiction research. 2010; 16: 229-231. [CrossRef]
  55. Singh D, Muller CP, Vicknasingam BK, Mansor SM. Social Functioning of Kratom (Mitragyna speciosa) Users in Malaysia. J Psychoactive Drugs. 2015; 47: 125-131. [CrossRef]
  56. Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. The Journal of the American Osteopathic Association. 2012; 112: 792-799.
  57. Babu K, McCurdy C, Boyer E. Opioid receptors and legal highs: Salvia divinorum and kratom. Clin Toxicol. 2008; 46: 146-152. [CrossRef]
  58. Harun N, Hassan Z, Navaratnam V, Mansor SM, Shoaib M. Discriminative stimulus properties of mitragynine (kratom) in rats. Psychopharmacology. 2015; 232: 2227-2238. [CrossRef]
  59. Sufka KJ, Loria MJ, Lewellyn K, Zjawiony JK, Ali Z, Abe N, et al. The effect of Salvia divinorum and Mitragyna speciosa extracts, fraction and major constituents on place aversion and place preference in rats. J Ethnopharmacol. 2014; 151: 361-364. [CrossRef]
  60. Ismail NI, Jayabalan N, Mansor SM, Muller CP, Muzaimi M. Chronic mitragynine (kratom) enhances punishment resistance in natural reward seeking and impairs place learning in mice. Addiction biology. 2016.
  61. Stogner JM. Predictions instead of panics: the framework and utility of systematic forecasting of novel psychoactive drug trends. The American journal of drug and alcohol abuse. 2015; 41: 519-526. [CrossRef]
  62. Guddat S, Gorgens C, Steinhart V, Schanzer W, Thevis M. Mitragynine (Kratom) - monitoring in sports drug testing. Drug testing and analysis. 2016. [CrossRef]
  63. McIntyre IM, Trochta A, Stolberg S, Campman SC. Mitragynine 'Kratom' related fatality: a case report with postmortem concentrations. Journal of analytical toxicology. 2015; 39: 152-155. [CrossRef]
  64. Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following Kratom (Mitragynina speciosa Korth) exposure. J Med Toxicol. 2010; 6: 424-426. [CrossRef]
  65. Neerman MF, Frost RE, Deking J. A drug fatality involving Kratom. Journal of forensic sciences. 2013; 58 Suppl 1: S278-279. [CrossRef]
  66. Karinen R, Fosen JT, Rogde S, Vindenes V. An accidental poisoning with mitragynine. Forensic Sci Int. 2014; 245C: e29-e32. [CrossRef]
  67. Galbis-Reig D. A Case Report of Kratom Addiction and Withdrawal. WMJ : official publication of the State Medical Society of Wisconsin. 2016; 115: 49-52; quiz 53.
  68. Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neuroscience and biobehavioral reviews. 2013; 37: 138-151. [CrossRef]
  69. Matsumoto K, Horie S, takayama H, Ishikawa H, Aimi N, Ponglux D, et al. Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2005; 78: 2-7. [CrossRef]
  70. Reanmongkol W, Keawpradub N, Sawangjaroen K. Effects of the extracts from Mitragyna speciosa Korth: leaves on analgesic and behavioral activites in experimental animals. Songklanakarin J Sci Technol. 2007; 29: 39-48.
  71. Shaik Mossadeq W, Sulaiman M, TA TM, Chiong H, Zakaria Z, Jabit M, et al. Anti-inflammatory and antinociceptive effects of Mitragyna specisoa Korth methanolic extract. Med Princ Pract. 2009; 18: 378-384. [CrossRef]
  72. Carpenter JM, Criddle CA, Craig HK, Ali Z, Zhang Z, Khan IA, et al. Comparative effects of Mitragyna speciosa extract, mitragynine, and opioid agonists on thermal nociception in rats. Fitoterapia. 2016; 109: 87-90. [CrossRef]
  73. Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, Ponglux D, et al. Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2004; 74: 2143-2155. [CrossRef]
  74. Boyer EW, Babu KM, Macalino GE. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict. 2007; 16: 352-356. [CrossRef]
  75. Havemann-Reinecke U. Kratom and alcohol dependence: clinical symptoms, withdrawal treatment and pharmacological mechanisms--a case report. Eur Psychiatry. 2011; 26: 1-50. [CrossRef]
  76. Goh TB, Koh RY, Mordi MN, Mansor SM. Antioxidant value and antiproliferative efficacy of mitragynine and a silane reduced analogue. Asian Pacific journal of cancer prevention : APJCP. 2014; 15: 5659-5665. [CrossRef]
  77. Saidin N, Randall T, Takayama H, Holmes E, Gooderham N. Malaysian Kratom, a phyto-pharmaceutical of abuse: studies on the mechanisms of its cytotoxicity. Toxicology. 2008; 253: 19-20. [CrossRef]
  78. Chittrakarn S, Keawpradub N, Sawangjaroen K, Kansenalak S, Janchawee B. The neuromuscular blockade produced by pure alkaloid, mitragynine and methanol extract of kratom leaves (Mitragyna speciosa Korth.). J Ethnopharmacol. 2010; 129: 344-349. [CrossRef]
  79. Matsumoto K, Yamamoto LT, Watanabe K, Yano S, Shan J, Pang PK, et al. Inhibitory effect of mitragynine, an analgesic alkaloid from Thai herbal medicine, on neurogenic contraction of the vas deferens. Life Sci. 2005; 78: 187-194. [CrossRef]
  80. Purintrapiban J, Keawpradub N, Kansenalak S, Chittrakarn S, Janchawee B, Sawangjaroen K. Study on glucose transport in muscle cells by extracts from Mitragyna speciosa (Korth) and mitragynine. Nat Prod Res. 2011; 25: 1379-1387. [CrossRef]
  81. Tsuchiya S, Miyashita S, Yamamoto M, Horie S, Sakai S, Aimi N, et al. Effect of mitragynine, derived from Thai folk medicine, on gastric acid secretion through opioid receptor in anesthetized rats. Eur J Pharmacol. 2002; 443: 185-188. [CrossRef]
Newsletter
Download PDF
0 0

TOP